AVEO PHARMACEUTICALS INC. REGISTERED SHARES DL -,001 Forum: Community User: isa

Das war ein Gewinn für das erste Quartal. Das bedeutet letztlich gar nichts, wie man an der Kursveränderung sehen kann. Aber es stimmt, die Aktie ist unterbewertet mit einem zugelassenen Medikament in vielen europäischen Ländern.

Die Analysten erwarteten einen Verlust und es wurde entgegen der Erwartungen Gewinn gemacht. Diese Aktie ist absolut unterbewertet. Nicht viele Biotecs machen Gewinn.

AVEO Reports First Quarter 2019 Financial Results and Provides Business Update Business Wire Business WireMay 9, 2019, 1:00 PM GMT 2 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- AVEO Oncology (AVEO) today reported financial results for the first quarter ended March 31, 2019 and provided a business update. “With a successful recent equity offering, together with the triggering of a FOTIVDA® (tivozanib) milestone from EUSA, AVEO’s strengthened balance sheet provides us with a cash runway that we expect will take us into the fourth quarter of 2020,” said Michael Bailey, president and chief executive officer of AVEO. “We remain committed to our goal of improving outcomes and patient experience in renal cell carcinoma (RCC), and look forward to reporting more mature interim OS results from our TIVO-3 study in advanced or metastatic RCC, which we expect will occur in the fourth quarter of 2019, as well as the subsequent decision regarding a potential NDA filing in the U.S. We also continue to make progress with the balance of our programs and pipeline, most notably the ongoing clinical collaborations combining FOTIVDA® with Bristol Myers Squibb’s OPDIVO® (nivolumab) for the TiNivo study in RCC and with AstraZeneca’s IMFINZI® (durvalumab) in first-*** hepatocellular carcinoma, ongoing studies of ficlatuzumab in multiple oncology indications, and the emerging potential of a new ocular formulation of tivozanib for the treatment of age-related macular degeneration.” Quelle Yahoo Finance

Earnings sind draußen ! CAMBRIDGE, Mass. (AP) _ AVEO Pharmaceuticals Inc. (AVEO) on Thursday reported first-quarter net income of $555,000, after reporting a loss in the same period a year earlier. The Cambridge, Massachusetts-based company said it had net income of 6 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 5 cents per share. The cancer drug company posted revenue of $1.6 million in the period. The company's shares closed at 91 cents. A year ago, they were trading at $2.23. Quelle Yahoo Finance

Ist doch verschoben worden

😉

😉

NEW YORK, NY / ACCESSWIRE / May 8, 2019 / AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM Eastern Time.

Ja ich weiß, bestimmt nachbörslich.

Ingo Acelrx heute Zahlen Laut Datum ✌🏻️

Ingo ✌🏻️

Acelrx würde ich dir raten mal auch auf die watchlist zu legen. Die haben die Zulassung und bereiten sich auf die Vermarktung vor. Sehe sie auf 8-10€ die nächste 12 Monate

Beobachte gerade beides Hier und Verastem. Mal schauen morgen gibts Q Zahlen bei Verastem.

Verastem gibt morgen Q1 zahlen bekannt. Sorry das ich einfach dazwischen schreibe

Mal auf die Watchlist....ich schau mir die Firma bei Gelegenheit mal genauer an.

Sehe gerade das du dich mehr für BIOS interessiert. Was hälst du von Verastem ? Richtig günstig im Moment ✌🏻️